The European Commission is looking into ways to support EU member states to address re-emerging preventable diseases and to increase vaccine coverage in Europe. This policy discussion is set against the background of an increase of vaccination hesitancy in several countries, vaccines shortages and vaccines R&D challenges. As part of this process, The European Commission has launched a public consultation.
The Global Health Network showcased its work at the recent ECTMIH 2017 conference in Antwerp. It was a pleasure to meet so many researchers working across varied areas of Global Health. Many thanks to those of you who stopped by the exhibition stand. There was a lot of interest in the network with over 250 signups for more information as well as many great conversations about our online tools and member-sites. Many of you shared some great suggestions for areas to look to develop further such as health economics and NTDs as well as ideas for new eLearning courses.
To highlight the types of activities run by The Global Health Network's innovative regional faculties, and how those can raise the capacity for research, dedicated faculty leaders Glory Oluwagbenga Ogunfowokun (Nigeria) and Jackeline Alger (Honduras) have created these video interviews
Abstract We investigated an outbreak of exanthematous illness in Maceió by using molecular surveillance; 76% of samples tested positive for chikungunya virus. Genetic analysis of 23 newly generated genomes identified the East/Central/South African genotype, suggesting that this lineage has persisted since mid-2014 in Brazil and may spread in the Americas and beyond.
All research studies on human subjects should have a level of quality and ethical standard assurance built into their operations to ensure that that the rights and well-being of human subjects are protected and that the data are reliable. This combined template and guide assists research teams in developing a QA plan for their study.
This guide will set out why quality management and monitoring is important and how it can be easily and practically built into a study.
A coherent four step plan for implementing in-house or reciprocal monitoring systems at a research site
There has been a trend over recent years towards the use of expensive contract organisations to monitor research studies and this can be expensive and is not necessary. This overview explains the reasons for reciprocal monitoring, and how it can benefit research groups.
One of the goals of the REDe network is to support the conduct of high quality research by providing tools, training and guidance in all the elements that are required. A very fundamental, but often overlooked, piece in this is the planning and implementation of research quality management (which is often referred to as monitoring).
Institut Pasteur Shanghai-Chinese Academy of Sciences (IPS-CAS), a partner of the ZIKAlliance consortium, announced that it has entered into a collaborative research agreement with Chongqing Zhifei Biological Products Stock Co., Ltd. (Zhifei) for the clinical studies and commercialization of a recombinant Zika virus subunit vaccine developed by IPS-CAS.
In response to the recent World Health Organisation (WHO) Global Vector Control Response document (http://www.who.int/malaria/global-vector-control-response/en/), ARCTEC at the London School of Hygiene & Tropical Medicine is working with The Global Health Network, the WHO and the Centres for Disease Control and Prevention (CDC) to develop an exciting new initiative called The Global Vector Hub. The project is being part-funded by an EU H2020 grant as part of the recently formed ZikaPLAN consortium. We have been invited by the Wellcome Trust to submit an application for a Biomedical Resource and Technology Development Grant to help fund the website. We have successfully advanced through the first round of grant proposals. The full application is now being prepared and is due for submission on 3rd April, 2017. To demonstrate the need for the Global Vector Hub, we are collecting letters of support from potential stakeholders. It would be great if you could distribute this e-mail to your contacts and ask them to provide letters of support.
The key message from this study is that the large uncertainty around the risk estimate needs to be further investigated because of a) the possible existence of co-factors that are yet to be validated, b) the assumptions that the authors needed to make in the absence of good data for the proportion of women who were infected during pregnancy.
We welcome contributions from members. Please submit an article for review by our editorial team.Upload now